Drugs / AFFITOPE AD02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01093664 | Oct 2009 → Jul 2010 | Alzheimer disease | Affiris AG | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00633841 Comparator | Feb 2008 → Sep 2009 | Alzheimer disease | Affiris AG | Completed | No outcome recorded |
| Phase 2 | NCT02008513 Comparator | Jun 2013 → Sep 2014 | Alzheimer disease | Affiris AG | Terminated | No outcome recorded |
| Phase 2 | NCT01117818 Comparator | Sep 2010 → Dec 2013 | Alzheimer disease | Affiris AG | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-09-17 | Inmune Bio, Inc. | Results INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints inmunebio.com ↗
An independent review confirmed a highly significant correlation (p<0.001) between baseline scores on EMACC and CDR-SB, the secondary endpoint in the AD02 trial. |
| 2024-06-27 | Inmune Bio, Inc. | Results INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial inmunebio.com ↗
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-17 | Inmune Bio, Inc. | INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints inmunebio.com ↗ |
| 2024-06-27 | Inmune Bio, Inc. | INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial inmunebio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFFITOPE AD02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00633841 ↗ |
| Known as | AD02 | “compared with AD02, a vaccine consisting of a peptide that mimics the N-terminal region of human amyloid-β (Aβ)” PMID 40953123 ↗ Sep 2025 |
| Modality | Vaccine | “we designed a new generation of AD vaccines” NCT00633841 ↗ |
| Route | Subcutaneous | “4 subcutaneous injections of IP in 4-week intervals” NCT00633841 ↗ |